We sought to better understand the effects of canagliflozin (cana) on multiple NOTCH1-mutated human T-ALL cell lines harbouring additional mutational backgrounds (broadly classified as PTEN−, Jurkat, RPMI8402 and CCRF-CEM or PTEN+, DND-41, HPB-ALL and CUTLL1). The gene discussed is PTEN; the disease is acute lymphoblastic leukemia.